Zeng Rui, Wang Xiao-Xuan, Cui Xi-He, Yang Qing, Zhu Xiao-Xin, Wang Ya-Jie
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2024 Apr;49(8):2222-2229. doi: 10.19540/j.cnki.cjcmm.20231212.704.
This study aims to investigate the effect and mechanism of Stellera chamaejasme extract(SCL) on multidrug resistance(MDR) in breast cancer. Human triple-negative breast cancer cell line MDA-MB-231 and its adriamycin-resistant cell line MDA-MB-231/ADR were used in the experiment. Cell viability was detected by methyl thiazolyl tetrazolium(MTT) assay, and cell apoptosis was detected by DAPI staining and Annexin-V/Pi double staining. Western blot(WB) was used to detect the expression levels of Keap1, Nrf2, HO-1, Bcl-2, Bax, caspase-9, and caspase-3. Immunofluorescence staining was used to observe the distribution of Nrf2 in the cell, and flow cytometry was used to detect the level of reactive oxygen species(ROS) in the cell. The results showed that the resis-tance factor of SCL was 0.69, and that of adriamycin and paclitaxel was 8.40 and 16.36, respectively. DAPI staining showed that SCL could cause nuclear shrinkage and fragmentation of breast cancer cells. Annexin-V/Pi double staining showed that the average apoptosis rate of the drug-resistant cells was 32.64% and 50.29%, respectively under medium and high doses of SCL. WB results showed that SCL could significantly reduce the expression levels of anti-apoptotic proteins Bcl-2, caspase-9, and caspase-3 and significantly increase the expression level of pro-apoptotic protein Bax. Further studies showed that SCL could significantly promote the expression of Keap1, significantly inhibit the expression of Nrf2 and HO-1, and significantly reduce the expression level of Nrf2 in the nucleus. Correspondingly, flow cytometry showed that the intracellular ROS level was significantly increased. In conclusion, SCL can significantly inhibit the proliferation of MDA-MB-231 multidrug-resistant cells of triple-negative breast cancer and cause cell apoptosis, and the mechanism is related to inhibiting Keap1/Nrf2 signaling pathway, leading to ROS accumulation in drug-resistant cells and increasing the expression of apoptosis-related proteins.
本研究旨在探讨瑞香狼毒提取物(SCL)对乳腺癌多药耐药(MDR)的影响及作用机制。实验采用人三阴性乳腺癌细胞系MDA-MB-231及其阿霉素耐药细胞系MDA-MB-231/ADR。采用甲基噻唑基四氮唑(MTT)法检测细胞活力,采用DAPI染色和膜联蛋白-V/碘化丙啶(Annexin-V/Pi)双染色法检测细胞凋亡。采用蛋白质免疫印迹法(WB)检测Kelch样环氧氯丙烷相关蛋白1(Keap1)、核因子E2相关因子2(Nrf2)、血红素加氧酶-1(HO-1)、B细胞淋巴瘤-2(Bcl-2)、Bax、半胱天冬酶-9(caspase-9)和半胱天冬酶-3(caspase-3)的表达水平。采用免疫荧光染色观察Nrf2在细胞内的分布,采用流式细胞术检测细胞内活性氧(ROS)水平。结果显示,SCL的耐药因子为0.69,阿霉素和紫杉醇的耐药因子分别为8.40和16.36。DAPI染色显示,SCL可导致乳腺癌细胞核固缩和碎裂。Annexin-V/Pi双染色显示,中、高剂量SCL作用下,耐药细胞的平均凋亡率分别为32.64%和50.29%。WB结果显示,SCL可显著降低抗凋亡蛋白Bcl-2、caspase-9和caspase-3的表达水平,显著增加促凋亡蛋白Bax的表达水平。进一步研究表明,SCL可显著促进Keap1的表达,显著抑制Nrf2和HO-1的表达,并显著降低细胞核内Nrf2的表达水平。相应地,流式细胞术显示细胞内ROS水平显著升高。综上所述,SCL可显著抑制三阴性乳腺癌MDA-MB-231多药耐药细胞的增殖并诱导细胞凋亡,其机制与抑制Keap1/Nrf2信号通路、导致耐药细胞内ROS蓄积及增加凋亡相关蛋白的表达有关。